Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherko Kuemmel

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2025
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid TumorsJavier Cortés, Araceli Priego, Elena Garralda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
JCO Clinical Cancer Informatics|November 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerDaniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, et al.
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Cancers|October 13, 2021
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast CancerNadia Harbeck, Raquel von Schumann, Ronald Ernest Kates, et al.
Breast Care (Basel, Switzerland)|March 16, 2026
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPTMichael Braun, Oleg Gluz, Sherko Kuemmel, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2025
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid TumorsJavier Cortés, Araceli Priego, Elena Garralda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.
Annals of Surgical Oncology|February 25, 2026
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 StudySherko Kuemmel, Peter A Fasching, Peter Schmid, et al.
Breast Cancer Research and Treatment|July 1, 2017
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
JCO Clinical Cancer Informatics|November 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerDaniel Kates-Harbeck, Hans Kreipe, Oleg Gluz, et al.
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
Breast Cancer Research and Treatment|January 12, 2019
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialUlrike Nitz, Oleg Gluz, Matthias Christgen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancerPeter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Cancers|October 13, 2021
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast CancerNadia Harbeck, Raquel von Schumann, Ronald Ernest Kates, et al.
Breast Care (Basel, Switzerland)|March 16, 2026
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPTMichael Braun, Oleg Gluz, Sherko Kuemmel, et al.
Pageof 9